RESTORE

Clinical Trial

NCT03406104 Completed

RESTORE

Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials (RESTORE)

Phase 3

Interventional

Disease

Disease type

Paediatric clinical trials

Orphan drug recognition

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

09/01/2018

Closing date

01/07/2022

Inclusion criteria :

Exclusion criteria :

Funding

industry

Members involved

Main investigators

Dr Catherine Vignal-Clermont

France

Neuro-Ophthalmology Rare Diseases (WG2)

Working Group Leader

Others investigators

Dr Claudia Priglinger

Representative

Germany

Pr Isabelle Audo

Representative

France

Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Neuro-Ophthalmology Rare Diseases (WG2), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)